Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Xiang Y, Zeng H, Liu X, Zhou H, Luo L, Duan C, Luo X, Yan H.

Biomed Rep. 2013 Jul;1(4):629-637. Epub 2013 May 28.

2.

Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(21):1-111. Epub 2010 Dec 1.

3.

Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review.

Tang JH, Zhang XL, Zhang ZH, Wang R, Zhang HM, Zhang ZL, Wang JH, Ren WD.

Chin Med J (Engl). 2011 May;124(10):1563-8. Review.

4.

Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.

Kumar Y, Gurusamy K, Pamecha V, Davidson BR.

Pancreas. 2007 Aug;35(2):114-9.

PMID:
17632316
5.

The proliferation marker thymidine kinase 1 in clinical use.

Zhou J, He E, Skog S.

Mol Clin Oncol. 2013 Jan;1(1):18-28. Epub 2012 Sep 4. Review.

7.

Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.

Kumar Y, Tapuria N, Kirmani N, Davidson BR.

Eur J Gastroenterol Hepatol. 2007 Mar;19(3):265-76. Review.

PMID:
17301655
8.
9.

Diagnostic value of microRNA for pancreatic cancer: a meta-analysis.

Wan C, Shen Y, Yang T, Wang T, Chen L, Wen F.

Arch Med Sci. 2012 Nov 9;8(5):749-55. doi: 10.5114/aoms.2012.31609. Epub 2012 Nov 7.

10.

A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma.

Sharif H, von Euler H, Westberg S, He E, Wang L, Eriksson S.

Vet J. 2012 Oct;194(1):40-7. doi: 10.1016/j.tvjl.2012.03.006. Epub 2012 Apr 18.

PMID:
22516918
11.

Can thymidine kinase levels in breast tumors predict disease recurrence?

O'Neill KL, Hoper M, Odling-Smee GW.

J Natl Cancer Inst. 1992 Dec 2;84(23):1825-8.

PMID:
1433372
12.

CT coronary angiography vs. invasive coronary angiography in CHD.

Gorenoi V, Schönermark MP, Hagen A.

GMS Health Technol Assess. 2012;8:Doc02. doi: 10.3205/hta000100. Epub 2012 Apr 16.

13.

Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.

He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S.

Oncol Rep. 2005 Oct;14(4):1013-9.

PMID:
16142366
14.

Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.

Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.

Chin J Dig Dis. 2006;7(3):170-4.

PMID:
16808798
15.

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.

Bjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Söderberg M, Sundquist M, Walz TM, Fernö M, Bergh J, Hatschek T.

Breast Cancer Res Treat. 2013 Jun;139(3):751-8. doi: 10.1007/s10549-013-2579-x. Epub 2013 Jun 5.

PMID:
23736998
16.

Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.

Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D.

Urology. 2010 Aug;76(2):513.e1-6. doi: 10.1016/j.urology.2010.04.034. Epub 2010 Jun 22.

PMID:
20573390
17.

Thymidine kinase 1 immunoassay: a potential marker for breast cancer.

Zhang F, Li H, Pendleton AR, Robison JG, Monson KO, Murray BK, O'Neill KL.

Cancer Detect Prev. 2001;25(1):8-15.

PMID:
11270425
18.

The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.

He Q, Zou L, Zhang PA, Lui JX, Skog S, Fornander T.

Int J Biol Markers. 2000 Apr-Jun;15(2):139-46.

PMID:
10883887
19.

Sensitive nonradiometric method for determining thymidine kinase 1 activity.

Ohrvik A, Lindh M, Einarsson R, Grassi J, Eriksson S.

Clin Chem. 2004 Sep;50(9):1597-606. Epub 2004 Jul 9.

20.

Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management.

Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J, He E, Eriksson S, Wen W, Skog S.

Mol Med Rep. 2009 Nov-Dec;2(6):923-9. doi: 10.3892/mmr_00000193.

PMID:
21475922
Items per page

Supplemental Content

Write to the Help Desk